FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 955-10 P/CON/DIV	SERIAL NO. 10/627,408
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Suthanthiran, et al.	CONFIRMATION NO. 2823
(Use several sheets if necessary)	FILING DATE July 25, 2003	GROUP 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BF			M. Maluccio, et al., "Angiotensin II Receptor Blockade: A Novel Strategy to Prevent Immunosuppressant-Associated Cancer Progression", *Transplantation Proceedings* (2001) Vol. 33, pp. 1820-1821.
BF			Hojo, et al., "Cyclosporine induces cancer progression by a cell-autonomous mechanism", *Nature* (1999) Vol., 397, pp. 530-534.
BF			Gary J. Nabel, "A transformed view of cyclosporine", *Nature* (1999) Vol. 397, pp. 471-472.
BF			Khanna, et al., "Regulation of new DNA Synthesis in Mammalian Cells by Cyclosporine", *Transplantation* (1994) Vol. 57, pp. 577-582. (Abstract)
BF			Kim, et al., "Immunosuppressive effects of 2-acetylaminofluorene and 2-aminofluorene on murine splenocytes culture", *Drug Chem Toxicol* (1989) Vol. 12, pp. 297-311. (Abstract)
BF			Tschmelitsch, et al., "Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil)", *Cancer Res* (1997) Vol. 57, No. 11, pp. 2181-2186. (Abstract)
BF			Baselga, et al., "Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies", *J. Natl. Cancer Inst.* (1993) Vol. 85, No. 16, pp. 1327-1333. (Abstract)
BF			Wolf, et al., "Angiotensin II-Induced Hypertrophy of Cultured Murine Proximal Tubular Cells is Mediated by Endogenous Transforming Growth Factor-β", *J. Clin. Invest.*, (1993) Vol. 92, pp. 1366-1373.
BF			Paine-Murrieta, et al., "Human tumor models in the severe combined immune deficient (*scid*) mouse", *Cancer Chemother Pharmacol* (1997), Vol. 40, pp. 209-214.
BF			Volpert, et al., "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats", *J. Clin. Invest.* (1996) Vol. 98, pp. 671-679.

EXAMINER [signature] DATE CONSIDERED 4/26/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.